oh dear sarepta´s eteplirsen targets dystrophin restoration and ATL1102 targets inflammation in DMD thats different interventions point . Whatever ANP likely needs to conduct a larger clinical trial with minimum 80+ patients but we will know the exact number soon .
DMD Phase 2 Results in Q4 = Potential 5000% Gem, page-215
Add PER (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
8.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $84.79M | |||
| Open | High | Low | Value | Volume |
| 8.1¢ | 8.2¢ | 8.0¢ | $126.2K | 1.570M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 13 | 983749 | 7.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 8.1¢ | 342843 | 3 |
View Market Depth
| Last trade - 10.43am 15/11/2024 (20 minute delay) ? |
| PER (ASX) Chart |